THE Therapeutic Goods
Administration has identified the
2013 seasonal influenza vaccines
for use in children and the timings
required.
Abbott’s Influvac, Novartis’
Agrippal, GlaxoSmithKline‘s Fluarix
and Sanofi-Pasteur’s Vaxigrip are
named for use from the age of 6
months while bioCSL’s Fluvax is
only to be used from the age of five
years because of an increased risk
of fever and febrile convulsions.
From the age of 9 years, no fever
or febrile issues apply.
Healthcare professionals are
encouraged to report all adverse
events associated with vaccination.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Mar 14
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.